TG Therapeutics (TGTX) Stock Price

TG Therapeutics Price

NASDAQ·CLOSED
64.13
​
Market closed

Revenue has compounded at 122.3% per year over the past 13 years to 616.29 M USD. Earnings per share have declined at 10.1% per year over the last 15 years. TG Therapeutics's net margin stands at 72.6%, up from -5,204.1% several years earlier. Analysts set a median price target of 80.50 USD, implying 25.5% above the current price. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus.

TG Therapeutics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TG Therapeutics business model & stock analysis

TG Therapeutics Inc is a biopharmaceutical company based in New York City, USA. The company was founded in 2012 and focuses on the development and commercialization of innovative therapy options for various types of cancer and autoimmune diseases. TG Therapeutics was founded as a result of a collaboration between Michael S. Weiss, an experienced investment banker and biotechnology manager, and Laurence N. Charous, an oncologist and clinical researcher. The company has roots in two predecessor companies: Manhattan Pharmaceuticals and LFB Biotechnologies. Both had failed, and TG rose from their remains. TG Therapeutics' business model is to develop a new therapy option by combining drugs of different drug classes that target the needs of patients with specific cancer conditions. The dual blockade approach, which simultaneously inhibits various signaling pathways that sustain tumor cells, is particularly promising. TG Therapeutics operates a diversified portfolio strategy and has several drug candidates in different stages of development for numerous cancer conditions, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' main products for cancer treatments currently are umapalisib and umbralisib, both of which are PI3K delta inhibitors and are being developed for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia. TG-1101 (Ublituximab) is a CD20-targeted antibody therapy used in lymphomas and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' research and development efforts are driven by an experienced team of oncologists and scientists, including CEO Michael S. Weiss. The company maintains close relationships with academic institutions and research facilities. TG Therapeutics holds a broad patent portfolio covering technologies and compounds that can be used in cancer and autoimmune disease treatment. In 2020, TG Therapeutics' revenue reached approximately $109 million, compared to $14 million in the previous year. This increase in revenue was due to the sales of umbralisib. However, the company has not yet received FDA approval for any of its drugs in the US. TG Therapeutics expects that the future success of the company will be based on the clinical activity of its pipeline, market acceptance of its products, and successful completion of studies and regulatory approvals. As of December 31, 2020, TG Therapeutics had 248 employees. The company's leading body, the board of directors, consists of an experienced team of executives and advisors, including Chairman and CEO Michael S. Weiss, CFO Sean A. Power, CMO Adam D. Feuerstein, and COO Scott T. Smith. TG Therapeutics has had a tumultuous past, but the company can now look forward to a promising pipeline and a very strong financial position. The research and development of this biopharmaceutical company are promising, and it remains to be seen which of the research products will actually break through and be introduced to the market.

Frequently asked questions about TG Therapeutics

The business model of TG Therapeutics Inc revolves around the development and commercialization of innovative biopharmaceutical products. Specializing in the field of oncology and B-cell malignancies, TG Therapeutics focuses on creating novel therapies to address the unmet medical needs of patients. By harnessing its expertise in research and development, the company aims to discover and develop targeted therapies that can improve the outcome and quality of life for individuals battling certain types of cancer. Through strategic partnerships, clinical trials, and regulatory initiatives, TG Therapeutics Inc strives to bring next-generation treatments to market, ultimately benefiting both patients and shareholders.

TG Therapeutics Inc is primarily active in the biotechnology and healthcare industries.

The main competitors of TG Therapeutics Inc in the market include pharmaceutical companies such as AbbVie Inc., Roche Holding AG, and Johnson & Johnson. These companies operate in similar therapeutic areas and have a strong presence in the market. TG Therapeutics Inc faces competition in the development and commercialization of therapies for various conditions, such as lymphoma and chronic lymphocytic leukemia.

TG Therapeutics Inc is a renowned biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases. Established in 1993, TG Therapeutics has emerged as a key player in the pharmaceutical industry, committed to advancing medical breakthroughs. With a focus on developing targeted therapies, the company has achieved significant milestones in its history. Over the years, TG Therapeutics has successfully introduced novel drugs and treatment options, catering to unmet medical needs. Their dedication to research and development, coupled with a strong commitment to patient care, has positioned TG Therapeutics Inc as a leading name in the healthcare sector.

TG Therapeutics Inc, a leading biopharmaceutical company, has achieved several significant milestones. Most notably, the company received accelerated approval from the U.S. Food and Drug Administration (FDA) for its innovative therapy, umbralisib, in combination with ublituximab, for the treatment of adult patients with marginal zone lymphoma (MZL) and follicular lymphoma (FL). This approval marks a major breakthrough in the field of oncology and reinforces TG Therapeutics Inc's commitment to developing effective treatments for hematologic malignancies. Additionally, the company has successfully completed various clinical trials, demonstrating the potential of its pipeline to address unmet medical needs.

TG Therapeutics Inc is primarily present in the United States. The company's headquarters are located in New York, and it focuses on the development and commercialization of novel treatments for various B-cell malignancies and autoimmune diseases. TG Therapeutics Inc primarily operates in the United States market, fostering collaborations with healthcare providers, research organizations, and regulatory authorities to advance its innovative therapies. With an unwavering commitment to improving patient outcomes, TG Therapeutics Inc continues to drive its presence and impact within the United States' healthcare landscape.

TG Therapeutics Inc represents a strong commitment to improving the lives of patients by developing innovative therapies in the field of hematological malignancies and autoimmune diseases. The company's corporate philosophy revolves around scientific excellence, patient-centricity, and collaborative partnerships. With a focus on research and development, TG Therapeutics Inc aims to bring transformative treatments to market that address unmet medical needs. Through its dedication to advancing medical science, this company strives to make a positive impact on the lives of patients, healthcare professionals, and the wider community.

Analysts currently set an average price target of 80.50 USD for the TG Therapeutics stock (median: 80.50 USD), implying +24.1 % versus the latest price. The consensus is based on 14 analyst ratings.

14 analysts currently rate the TG Therapeutics stock: 12 recommend buying, 1 holding and 1 selling. For 2026, analysts expect TG Therapeutics to generate revenue of 993.71 M USD and earnings per share of 1.03 USD.

Converted at the current exchange rate, the TG Therapeutics share trades at 58.40 EUR (64.13 USD).

The TG Therapeutics share (TGTX) is listed on 7 stock exchanges, including: NASDAQ (TGTX), London (0VGI.L), SIX (Zürich) (NKB2.SW), Frankfurt (NKB2.F), München (NKB2.MU), Düsseldorf (NKB2.DU).

TG Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapies for cancer and autoimmune diseases. The company's business model includes the development of new drugs and their marketing. The company is divided into various divisions, each focused on specific therapy areas. These divisions include both cancer therapies and immunotherapies used in autoimmune diseases. Each division is led by highly qualified researchers specialized in researching specific types of cancer and autoimmune diseases and collaborate closely to discover advanced technologies. TG Therapeutics' flagship product is the BTK inhibitor Umbralisib, used in various cancers such as lymphomas or leukemias. This drug is a particularly potent molecule specifically developed for its effect on B lymphocytes. By inhibiting these cells, the division of cancer cells is inhibited, stopping the growth of tumor cells. The medication has great potential in treating cancer patients who do not respond to other therapies. In the field of immunotherapy, the company is developing products such as Ublituximab, used in the treatment of autoimmune diseases such as multiple sclerosis. This drug inhibits the activation of B cells, reducing excessive immune reactions in patients. This leads to a decrease in the number of relapses or symptoms of autoimmune diseases and slows down the progression of the disease. TG Therapeutics follows a business-to-business model, forming partnerships with other companies to market its products. However, the company also has extensive sales and marketing capabilities to sell its products directly to hospitals and medical facilities. There is a particular focus on multiple markets, especially in the USA, Europe, and Asia. The company generates revenue through product sales and partnerships with other biotech companies. These partnerships include research agreements and licensing agreements, where the company licenses its technologies and products to other firms for fees. Thus, TG Therapeutics generates income from various revenue streams and is able to continue its research and development and expand its business. In summary, TG Therapeutics' business model is focused on the development of innovative therapies for cancer and autoimmune diseases. Through the close collaboration between researchers and developers, the company has developed a range of therapies that can be used to treat various diseases. The company aims to market its products globally to maximize its success and increase its value for patients and investors.

The expected revenue of TG Therapeutics is 993.71 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of TG Therapeutics is 164.20 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of TG Therapeutics is currently 62.24. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the TG Therapeutics stock.

The price-to-sales ratio (P/S) of TG Therapeutics is currently 10.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the TG Therapeutics stock.

The Eulerpool Quality Score for TG Therapeutics is 7/10.

The ISIN of TG Therapeutics is US88322Q1085. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of TG Therapeutics is A1JXW7. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of TG Therapeutics is TGTX. The ticker symbol is used to trade TG Therapeutics shares on the stock exchange.

Fair ValueTerminal
60.28 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
1.54 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Dec 14, 1995
ISIN
US88322Q1085
Cusip
88322Q108
Sedol
B828K63
Market capitalization
10.18 B USDLarge Cap
52-Week Range
PEG
0.61
P/E ratio
P/Ee 2026
62.00
P/Ee 2027
23.13
P/Ee 2028
17.29
P/Ee 2029
15.93
P/Ee 2030
12.72
P/Se
10.28
EV/EBIT
84.02
P/B Ratio
15.71
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
49.21 %
Last updated Nov 21, 2026, 3:34 AM

TG Therapeutics Ticker

DÜSSELDORF · NKB2.DUFRANKFURT · NKB2.FLONDON · 0VGI.LLONDON STOCK EXCHANGE · 0VGI.LMUNICH · NKB2.MUNASDAQ · TGTXSIX · NKB2.SW

TG Therapeutics FIGI

TGTX:US · BBG000FVZQY1TGTX:UA · BBG000FVZRM2TGTX:UC · BBG000FVZRW1TGTX:UN · BBG000FVZT11TGTX:UP · BBG000FVZTM8TGTX:UB · BBG000FVZVM3TGTX:UM · BBG000FVZX03TGTX:UX · BBG000FVZXC0TGTX:UR · BBG000FVZXZ5TGTX:UD · BBG000FW00K9TGTX:UF · BBG000FW04J3TGTX:VY · BBG000FW0591